ResearcherNational Taiwan UniversityNo recent work listed
Che‐Ming Teng
Matched on ORCID iD 0000-0002-9719-7334; OpenAlex author ID A5016825023. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper
Papers 2
- Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Co-author DOI 10.1186/s13148-019-0681-6↗
- Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-mediated angiogenesis. Last author DOI 10.1016/j.ajpath.2013.04.022↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Li-Hsun Chang · 2 shared papers, 2013–2019 · strength 0.14
- Paper Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor b… DOI 10.1186/s13148-019-0681-6↗
- Paper Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-media… DOI 10.1016/j.ajpath.2013.04.022↗
- Shiow‐Lin Pan · 2 shared papers, 2013–2019 · strength 0.14
- Paper Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor b… DOI 10.1186/s13148-019-0681-6↗
- Paper Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-media… DOI 10.1016/j.ajpath.2013.04.022↗
- Chao-Di Chang · 1 shared paper, 2019 · strength 0.10
- Min‐Wu Chao · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.